Moteur de recherche d’entreprises européennes

Financement de l’UE (1 034 075 €) : La première « empreinte numérique » au monde pour les échantillons de sang humain. Hor 13/03/2020 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

La première « empreinte numérique » au monde pour les échantillons de sang humain.

"Smart4Diagnostics (S4DX) has developed the world’s first “digital human sample data-fingerprint” for human blood samples in pre-preanalytics. We aks for EIC-support to catapult this innovation into a market-changing product. S4DX detects and reduces pre-preanalytical errors at sample collection when patients are still present. This is a quantum leap in quality and safety for patients, doctors and laboratories. They receive reliable results and painful re-visits and re-collection of samples are avoided. With our innovation we change medical diagnostics from ""trust-based” to “evidence-based”. We provide a complete dataset on the quality of each human sample from blood draw until analysis. Our solution provides the new pre-preanalytical data-standard for sensitive medical diagnostics in the future. S4DX “digital human sample fingerprint” will be the necessary data-baseline for highly sensitive tests (e.g. liquid biopsy). Market-entry in Europe with our MVP is planned for Dec. 2020. Our data will be used to refine our pattern-recognition algorithms and thus provide the basis for personalized and precision diagnostics. We collaborate with leading international partners. Roche Diagnostics and Sarstedt are technical advisors, leading European lab chains (Bioscientia/Germany, Medisupport/Switzerland and Certe/ Netherlands) are implementation partners; Würth Electronics provides access to manufacturers and supply chain partners. The company was founded in Jan. 2018, won the EIT-Health Wildcard as best eHealth start-up in Europe, the Hackathon of the TU Munich/Germany as best start-up and was chosen globally by the WHO as one of ten most promising start-ups in 2018. In April 2019 the Investment committee of the High-Tech-Gründerfonds voted unanimously to accept S4DX for further investment of 1 Mio. €, in July 2019 ACI/ Boston accepted us as one of six companies globally in the “Gold-Track-Program” for massive global scaling in healthcare. "


Smart4Diagnostics GmbH 1 034 075 €

https://cordis.europa.eu/project/id/945530

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Smart4Diagnostics GmbH, Munich, Allemagne.